Abstract
purpose. Methylprednisolone (MP) is commonly used to treat traumatic optic neuropathy and optic neuritis, but its benefit in terms of neuronal survival remains controversial. The aim of this study was to investigate the effects of MP on retinal ganglion cell (RGC) survival and visual function after ischemia in rats.
methods. Ocular ischemia was induced by elevated intraocular pressure. Rats were treated with NaCl, 1 mg/kg/d, or 30 mg/kg/d intraperitoneal MP over 3 days. RGCs were labeled retrogradely 4 days after ischemia and were quantified 6 days later. Post-ischemic retinal function was assessed by scotopic and photopic electroretinography (ERG). Optic nerve function was investigated on days 4 and 10 after ischemia by visual evoked potentials (VEPs).
results. Compared with nonischemic eyes, ischemia reduced RGCs with NaCl to 47% ± 3% (mean ± SEM) and to 46% ± 3% and 43% ± 6% with 1 mg/kg/d and 30 mg/kg/d MP. ERG did not differ significantly for any parameter among the three groups. Four days after ischemia, the VEPs of rats receiving any dose of MP were significantly higher than the control. VEPs in both steroid groups fell to control levels 10 days after ischemia.
conclusions. Treatment with MP did not improve RGC survival or retinal function. The VEP showed a short-term benefit because of steroids.
Glucocorticoids are natural steroid hormones. Evidence that glucocorticoids are effective in the treatment of central nervous system injury came from different animal models
1 2 3 and from clinical studies for inflammatory
4 5 and traumatic diseases.
6 Based on those data, glucocorticoids were used in ophthalmology to treat traumatic optic nerve injury
7 and optic neuritis.
8 However, clinical evidence that glucocorticoids improve the survival of retinal ganglion cells (RGCs) is lacking. The International Optic Nerve Trauma Study did not find a clear benefit after glucocorticoid treatment,
9 and optic nerve atrophy does not seem to be affected by glucocorticoids after optic neuritis.
10 Doubts about the neuroprotective effects of glucocorticoids were supported by an animal study,
11 and recent studies suggested pro-apoptotic effects on RGCs in a model of experimental autoimmune encephalomyelitis
12 and after optic nerve crush.
13
The aim of the present study was to investigate the hypothesis that methylprednisolone (MP) has neuroprotective properties in the retina. We approached this question using transient ocular ischemia as a standardized damage model for retinal ganglion cells whereby functional and morphologic deficits are induced by interruption of the blood supply. This model was chosen to minimize the confounding beneficial effects of MP, such as the reduction of inflammation and traumatic edema. We assessed the number of vital RGCs, the retinal function by electroretinography (ERG), and the visual pathway by evaluating temporal contrast vision with visual evoked potentials (VEPs).
14 MP was injected intraperitoneally in two different dosages directly after ischemia and on the first and second days thereafter: 1 mg/kg/d as a standard anti-inflammatory dosage and 30 mg/kg/d as equivalent to that of the Second National Acute Spinal Cord Injury Study.
6
Rats were anesthetized, and the anterior chamber of the left eye was cannulated with a 30-gauge needle connected to a reservoir containing 0.9% NaCl. Intraocular pressure was increased to 120 mm Hg for 55 minutes, and ischemia was confirmed by retinal edema and stases in retinal arteries. Rats without recovery of retinal perfusion in the first 3 minutes after the ischemic period, or those with lens injuries, were excluded. Twenty-six rats underwent ischemia and were divided into three groups: saline (n = 10) at 1 mg/kg/d, MP (n = 7), and 30 mg/kg/d MP (n = 9) for 3 days.
VEPs and photopic-flicker ERG responses were extracted by Fourier analysis (Igor Pro 5.01; WaveMetrics, Lake Oswego, OR). Spectra magnitudes, including the third harmonic, were added up in VEPs. For the scotopic ERG, the a-wave was calculated as the difference between the baseline and the trough of the first negative deflection. Conventional b-wave amplitude was the difference between the a-wave’s trough and the b-wave’s peak. Oscillatory potentials were extracted as a bandpass of 75 Hz to 300 Hz from the unattenuated scotopic flash ERG and were quantified as the difference between the highest peak and the lowest trough. All averaged data are presented as mean ± SEM. Statistical significance was assessed using ANOVA followed by Tukey-Kramer post hoc testing corrected for multiple comparisons. Differences were considered significant at P < 0.05. Power analysis was performed with a researcher toolkit (DDS Research, Inc., Fort Worth, TX; http://www.dssresearch.com/toolkit/spcalc/powera2.asp) using the two-tail approach.
Our aim was to assess whether MP would reveal neuroprotective effects on retinal neurons in an in vivo model independent of inflammation or direct axonal injury. To our knowledge, the effects of MP to protect retinal cells after ischemia have not been published before. We demonstrated that MP did not affect RGC survival, retinal function, or final optic nerve function.
The rationale for choosing two different concentrations of MP was adapted from the commonly used clinical dose. Even if MP is not usually applied after ischemic insult, we chose the transient-ischemia model because it allows functional and morphologic testing. Neuroprotection is typically quantified by the amount of cell loss. We detected no difference in cell count between the MP-injected rats and those injected with NaCl 0.9% solution. This was surprising because MP elicits multiple protective cellular actions, such as inhibiting arachidonic acid metabolism
15 and lipid peroxidation,
16 17 stabilizing lysosomal membranes,
18 reducing basal metabolic energy,
19 lowering lactate accumulation,
20 and enhancing the expression of heat-shock proteins.
21 However, neuroprotection has been demonstrated in the retinal ischemia model with other substances, such as memantine.
22
In addition to counting RGCs, we recorded VEPs and ERGs to assess the remaining function after ischemia. Retinal function was markedly reduced, but not abolished, after ischemia, with the b-wave more affected than the a-wave, indicating a different sensitivity of cell populations to ischemia, as shown in earlier publications.
14 23 24 MP did not affect the function of inner retinal neurons such as photoreceptors and bipolar cells; it neither damaged nor preserved them, whereas other substances can preserve or improve post-ischemic retinal function.
25 26
VEP decreased after retinal ischemia. The relatively small decrease of potentials, especially in the 7.5-Hz stimulation group, is initially surprising given the marked loss of retinal function. However, the loss of function as assessed with the VEP is only loosely correlated with the amount of cell loss in earlier studies.
27 28 29 For instance, in monkey experimental glaucoma, Johnson et al.
29 showed that a loss of 91% of the ganglion cells reduces the flash VEP down to only 64%. Four days after ischemia, the VEPs of rats receiving MP were significantly higher than those of controls; 6 days later, the VEPs in both steroid groups fell to control levels. MP may well have delayed cell death or improved the excitation of the surviving cells, leading to the better initial function.
Even considering the RGC, ERG, and VEP results together, MP did not influence cell survival or visual function after ischemia. We do think that the lack of steroid efficacy is not simply a dosage problem because we applied two dosages that differed by a factor of 30. Previous studies found neuroprotective effects of MP on neuronal
30 31 32 and retinal
33 tissue after intraperitoneal injection in rats with similar dosages. However, we hypothesize that the neuroprotective
1 2 3 and pro-apoptotic
12 effects balanced each other. Thus, treatment with none of the concentrations seemed to influence retinal neurons after ischemia. A similar situation has been found for optic nerve injury in the adult rat.
11
In summary, we report negative and positive findings with clinical relevance. First, the results suggest that methylprednisolone treatment is not effective in ameliorating retinal injury induced by ischemia. Second, the treatment also did not impair visual function or reduce RGC survival.
Supported by the Ernst und Berta Grimmke-Stiftung, Germany.
Submitted for publication February 13, 2008; revised May 29, 2008; accepted September 2, 2008.
Disclosure:
C. Dimitriu, None;
M. Bach, None;
W.A. Lagrèze, None;
T. Jehle, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Thomas Jehle, University Eye Hospital Freiburg, Killianstrasse 5, 79106 Freiburg im Breisgau, Germany;
[email protected].
BraughlerJM, HallED, MeansED, WatersTR, AndersonDK. Evaluation of an intensive methylprednisolone sodium succinate dosing regimen in experimental spinal cord injury. J Neurosurg. 1987;67:102–105.
[CrossRef] [PubMed]Gonzalez DeniselleMC, GonzalezSL, De NicolaAF. Cellular basis of steroid neuroprotection in the wobbler mouse, a genetic model of motoneuron disease. Cell Mol Neurobiol. 2001;21:237–254.
[CrossRef] [PubMed]HallED, BraughlerJM, McCallJM. Antioxidant effects in brain and spinal cord injury. J Neurotrauma. 1992.(suppl 1)S165–S172.
KulkarniAP, KellawayLA, LahiriDK, KotwalGJ. Neuroprotection from complement-mediated inflammatory damage. Ann N Y Acad Sci. 2004;1035:147–164.
[CrossRef] [PubMed]BrusaferriF, CandeliseL. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol. 2000;247:435–442.
[CrossRef] [PubMed]BrackenMB, ShepardMJ, CollinsWF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405–1411.
[CrossRef] [PubMed]SteinsapirKD. Traumatic optic neuropathy. Curr Opin Ophthalmol. 1999;10:340–342.
[CrossRef] [PubMed]SpoorTC, RockwellDL. Treatment of optic neuritis with intravenous megadose corticosteroids: a consecutive series. Ophthalmology. 1988;95:131–134.
[CrossRef] [PubMed]LevinLA, BeckRW, JosephMP, SeiffS, KrakerR. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology. 1999;106:1268–1277.
[CrossRef] [PubMed]HickmanSJ, KapoorR, JonesSJ, AltmannDR, PlantGT, MillerDH. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74:1139–1141.
[CrossRef] [PubMed]OhlssonM, WesterlundU, LangmoenIA, SvenssonM. Methylprednisolone treatment does not influence axonal regeneration or degeneration following optic nerve injury in the adult rat. J Neuroophthalmol. 2004;24:11–18.
[CrossRef] [PubMed]DiemR, HobomM, MaierK, et al. Methylprednisolone increases neuronal apoptosis during autoimmune CNS inflammation by inhibition of an endogenous neuroprotective pathway. J Neurosci. 2003;23:6993–7000.
[PubMed]SteinsapirKD, GoldbergRA, SinhaS, HovdaDA. Methylprednisolone exacerbates axonal loss following optic nerve trauma in rats. Restor Neurol Neurosci. 2000;17:157–163.
[PubMed]JehleT, WingertK, DimitriuC, et al. Quantification of ischemic damage in the rat retina: a comparative study using evoked potentials, electroretinography, and histology. Invest Ophthalmol Vis Sci. 2008;49:1056–1064.
[CrossRef] [PubMed]KatayamaY, ShimizuJ, SuzukiS, et al. Role of arachidonic acid metabolism on ischemic brain edema and metabolism. Adv Neurol. 1990;52:105–108.
[PubMed]HallED, BraughlerJM. Effects of intravenous methylprednisolone on spinal cord lipid peroxidation and Na+ + K+)-ATPase activity: dose-response analysis during 1st hour after contusion injury in the cat. J Neurosurg. 1982;57:247–253.
[CrossRef] [PubMed]TaokaY, OkajimaK, UchibaM, JohnoM. Methylprednisolone reduces spinal cord injury in rats without affecting tumor necrosis factor-alpha production. J Neurotrauma. 2001;18:533–543.
[CrossRef] [PubMed]HinzB, HirschelmannR. Dexamethasone megadoses stabilize rat liver lysosomal membranes by non-genomic and genomic effects. Pharm Res. 2000;17:1489–1493.
[CrossRef] [PubMed]TuorUI. Glucocorticoids and the prevention of hypoxic-ischemic brain damage. Neurosci Biobehav Rev. 1997;21:175–179.
[CrossRef] [PubMed]FarooqueM, HilleredL, HoltzA, OlssonY. Effects of methylprednisolone on extracellular lactic acidosis and amino acids after severe compression injury of rat spinal cord. J Neurochem. 1996;66:1125–1130.
[PubMed]BarrCS, DokasLA. Glucocorticoids regulate the synthesis of HSP27 in rat brain slices. Brain Res. 1999;847:9–17.
[CrossRef] [PubMed]LagrezeWA, KnorleR, BachM, FeuersteinTJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci. 1998;39:1063–1066.
[PubMed]KatanoH, IshiharaM, ShiraishiY, KawaiY. Effects of aging on the electroretinogram during ischemia-reperfusion in rats. Jpn J Physiol. 2001;51:89–97.
[CrossRef] [PubMed]MukaidaY, MachidaS, MasudaT, TazawaY. Correlation of retinal function with retinal histopathology following ischemia-reperfusion in rat eyes. Curr Eye Res. 2004;28:381–389.
[CrossRef] [PubMed]RothS, ShaikhAR, HennellyMM, LiQ, BindokasV, GrahamCE. Mitogen-activated protein kinases and retinal ischemia. Invest Ophthalmol Vis Sci. 2003;44:5383–5395.
[CrossRef] [PubMed]Mayor-TorroglosaS, De la VillaP, RodriguezME, et al. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46:3825–3835.
[CrossRef] [PubMed]FrommerGP, GalambosR, NortonTT. Visual evoked responses in cats with optic tract lesions. Exp Neurol. 1968;21:346–363.
[CrossRef] [PubMed]HobomM, StorchMK, WeissertR, et al. Mechanisms and time course of neuronal degeneration in experimental autoimmune encephalomyelitis. Brain Pathol. 2004;14:148–157.
[CrossRef] [PubMed]JohnsonMA, DrumBA, QuigleyHA, SanchezRM, DunkelbergerGR. Pattern-evoked potentials and optic nerve fiber loss in monocular laser-induced glaucoma. Invest Ophthalmol Vis Sci. 1989;30:897–907.
[PubMed]TuorUI, ChumasPD, Del BigioMR. Prevention of hypoxic-ischemic damage with dexamethasone is dependent on age and not influenced by fasting. Exp Neurol. 1995;132:116–122.
[CrossRef] [PubMed]VaqueroJ, ZuritaM, OyaS, AguayoC, BonillaC. Early administration of methylprednisolone decreases apoptotic cell death after spinal cord injury. Histol Histopathol. 2006;21:1091–1102.
[PubMed]KaptanogluE, SolarogluI, SurucuHS, AkbiyikF, BeskonakliE. Blockade of sodium channels by phenytoin protects ultrastructure and attenuates lipid peroxidation in experimental spinal cord injury. Acta Neurochir (Wien). 2005;147:405–412.discussion 412
[CrossRef] [PubMed]SolbergY, DubinskiG, TchirkovM, BelkinM, RosnerM. Methylprednisolone therapy for retinal laser injury. Surv Ophthalmol. 1999;44(suppl 1)S85–S92.
[CrossRef] [PubMed]